France's health minister wants to limit use of a popular malaria drug as a coronavirus treatment after a new study found it ineffective and warned of increased health risks.
Olivier Veran tweeted Saturday that he asked France's public health council to draft new rules for prescribing hydroxychloroquine and other treatments within 48 hours.
He specifically cited a study of 100,000 patients worldwide, published Friday in the Lancet, saying hydroxychloroquine and related drug chloroquine were ineffective against the virus and were tied to a greater risk of death and heart rhythm problems.
Prominent French virologist Dr. Didier Raoult drew international attention including from U.S. President Donald Trump for his research early in the pandemic suggesting hydroxychloroquine reduced virus symptoms. Raoult's office didn't comment on the minister's move.
France included the drug in a trial of multiple treatments and allowed its use for hospitalized patients.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
